According to a report by Technavio titled "Nicotine Patch Market by Product and Geography - Forecast and Analysis 2022-2026", the nicotine patch market is projected to have a CAGR of 7.55% during the forecast period, indicating accelerated growth. Technavio analysts have classified the global nicotine patch market as a part of the pharmaceutical market within the entire healthcare industry.
Strict regulation is set to be the primary challenge for the nicotine patch market within the forecast period. Participants in the global nicotine patch market must adhere to strict rules and regulations implemented by different governmental bodies in each country to monitor the sale of tobacco products. In the United States, suppliers must comply with regulations set by the FDA. Quit-smoking products are governed by the FDA's Center for Drug Evaluation and Research, which is responsible for ensuring product safety. In India, advertising of nicotine-based products is prohibited.
According to the report, the market share for 24-hour nicotine patches is expected to grow significantly during the forecast period. In 2021, the 24-hour nicotine patch will be the largest product segment in the global nicotine patch market. There are three variants of the 24-hour nicotine patch: 21mg, 14mg, and 7mg. Technological innovations have injected vitality into the global 24-hour nicotine patch market.
The report lists the top five nicotine patch companies, with British American Tobacco Limited being one of them. The company offers nicotine patches under its Velo brand, which contains high-purity nicotine, water, and other high-quality ingredients.
Cardinal Health Inc. delivers nicotine patches including nicotine transdermal systems and 21mg nicotine.
Cipla Health Ltd. offers nicotine patches, such as Nicotex patches, which are transdermal patches that utilize nicotine replacement therapy to aid in smoking cessation.
CVS Health Corp. offers nicotine patches, such as the CVS Smoking Cessation Patch, to aid in smoking cessation.
Reddys Laboratories Ltd. is a company that offers nicotine patches, specifically Habitrol nicotine patches.
In addition, other nicotine patch companies involved in the research include Cigna Corporation, Itaconix Corporation, Merck KGaA, Novartis AG, Perrigo Company Plc, Pfizer Inc., Pierre Fabre SA, Lundbeck Pharmaceuticals Ltd., Target Corporation, Walgreens Boots Alliance Inc., Walmart Inc., GlaxoSmithKline plc, and Johnson & Johnson.
Statement
This article is compiled from third-party information and is intended for industry communication and learning purposes only.
This article does not represent the views of 2FIRSTS and we are unable to confirm the authenticity and accuracy of its content. The compilation of this article is intended solely for industry exchange and research purposes.
Due to limitations in our translation abilities, the translated article may not fully reflect the original text. Please refer to the original text to ensure accuracy.
2FIRSTS maintains complete alignment with the Chinese government regarding any statements or positions concerning domestic issues, as well as those that involve Hong Kong, Macau, Taiwan, or foreign affairs.
The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
